Evidence map›Paper›PMID 26232236›Full record

ReviewAmerican journal of physiology. Heart and circulatory physiology2015

Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21.

Eleni M Domouzoglou, Katerina K Naka, Antonios P Vlahos, Michail I Papafaklis, Lampros K Michalis, Agathoklis Tsatsoulis, Eleftheria Maratos-Flier

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of physiology. Heart and circulatory physiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eleni M DomouzoglouDepartment of Pediatrics, Medical School, University of Ioannina, Ioannina, Greece;
Katerina K NakaSecond Department of Cardiology, Medical School, University of Ioannina, Ioannina, Greece;
Antonios P VlahosDepartment of Pediatrics, Medical School, University of Ioannina, Ioannina, Greece;
Michail I PapafaklisSecond Department of Cardiology, Medical School, University of Ioannina, Ioannina, Greece;
Lampros K MichalisSecond Department of Cardiology, Medical School, University of Ioannina, Ioannina, Greece;
Agathoklis TsatsoulisDepartment of Endocrinology, Medical School, University of Ioannina, Ioannina, Greece;
Eleftheria Maratos-FlierDivision of Endocrinology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts emaratos@bidmc.harvard.edu.

Funding

Metabolic Actions of FGF21R01DK028082 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FLIER, JEFFREY S · 1987 to 2018
$5.0M
NIDDK NIH HHS R01 DK028082
6 · The paper itself

Abstract

Early detection of risk factors for enhanced primary prevention and novel therapies for treating the chronic consequences of cardiovascular disease are of the utmost importance for reducing morbidity. Recently, fibroblast growth factors (FGFs) have been intensively studied as potential new molecules in the prevention and treatment of cardiovascular disease mainly attributable to metabolic effects and angiogenic actions. Members of the endocrine FGF family have been shown to increase metabolic rate, decrease adiposity, and restore glucose homeostasis, suggesting a multiple metabolic role. Serum levels of FGFs have been associated with established cardiovascular risk factors as well as with the severity and extent of coronary artery disease and could be useful for prediction of cardiovascular death. Furthermore, preclinical investigations and clinical trials have tested FGF administration for therapeutic angiogenesis in ischemic vascular disease, demonstrating a potential role in improving angina and limb function. FGF21 has lately emerged as a potent metabolic regulator with multiple effects that ultimately improve the lipoprotein profile. Early studies show that FGF21 is associated with the presence of atherosclerosis and may play a protective role against plaque formation by improving endothelial function. The present review highlights recent investigations suggesting that FGFs, in particular FGF21, may be useful as markers of cardiovascular risk and may also serve as protective/therapeutic agents in cardiovascular disease.

Indexed as

AtherosclerosisCardiovascular DiseasesCoronary Artery DiseaseEndothelium, VascularFibroblast Growth FactorsHumansNeovascularization, PhysiologicPlaque, Atheroscleroticfibroblast growth factor 21Fibroblast Growth Factorsangiogenesisatherosclerosisbiomarkercoronary artery diseasefibroblast growth factor

Identifiers

PMID26232236
PMCPMC4747916

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.